Overview
Polyhydramnios-megalencephaly-symptomatic epilepsy syndrome, sometimes called PMSE syndrome or Pretzel syndrome, is a rare brain disorder that affects children from birth. The name describes three of its main features: polyhydramnios (too much fluid around the baby during pregnancy), megalencephaly (an unusually large brain), and epilepsy (recurring seizures that are hard to control). The condition is caused by changes in a gene called STE20-related kinase adaptor alpha (STRADA), which plays an important role in how brain cells grow and develop. When this gene does not work properly, brain cells grow too much and in the wrong way, leading to the features seen in this syndrome. Children with PMSE syndrome typically have a very large head, severe intellectual disability, and seizures that begin in infancy and are often difficult to treat with standard medications. Many children also have low muscle tone (hypotonia), making it hard to sit, stand, or walk. Some children may have breathing problems or feeding difficulties in early life. The syndrome was first described in the Old Order Mennonite community in North America, where it is more commonly found due to a founder effect. There is currently no cure for PMSE syndrome. Treatment focuses on managing seizures with anti-epileptic medications and supporting development through physical, occupational, and speech therapy. Some research has explored targeted treatments based on the biology of the STRADA gene pathway, but these remain experimental. Families and caregivers play a central role in supporting children with this condition throughout their lives.
Also known as:
Key symptoms:
Unusually large head and brain (megalencephaly)Severe intellectual disabilityRecurring seizures that are hard to control (epilepsy)Low muscle tone (hypotonia) making movement difficultDelayed or absent ability to sit, stand, or walkLittle or no speech developmentFeeding difficulties in infancyBreathing problems in some infantsExcess fluid around the baby during pregnancy (polyhydramnios)Abnormal brain structure seen on MRI scans
Clinical phenotype terms (34)— hover any for plain English
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for Polyhydramnios-megalencephaly-symptomatic epilepsy syndrome.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Polyhydramnios-megalencephaly-symptomatic epilepsy syndrome at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Polyhydramnios-megalencephaly-symptomatic epilepsy syndrome.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Polyhydramnios-megalencephaly-symptomatic epilepsy syndrome.
Community
No community posts yet. Be the first to share your experience with Polyhydramnios-megalencephaly-symptomatic epilepsy syndrome.
Start the conversation →Latest news about Polyhydramnios-megalencephaly-symptomatic epilepsy syndrome
No recent news articles for Polyhydramnios-megalencephaly-symptomatic epilepsy syndrome.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.Which anti-epileptic medications are most likely to help my child, and what are the side effects?,Is my child a candidate for any clinical trials or experimental treatments like rapamycin?,What therapies (physical, occupational, speech) should my child start, and how often?,Should other family members be tested as carriers of the STRADA gene change?,What should I do if my child has a prolonged seizure at home?,Are there any specialists or centers with specific experience treating PMSE syndrome?,What support services and resources are available for our family?
Common questions about Polyhydramnios-megalencephaly-symptomatic epilepsy syndrome
What is Polyhydramnios-megalencephaly-symptomatic epilepsy syndrome?
Polyhydramnios-megalencephaly-symptomatic epilepsy syndrome, sometimes called PMSE syndrome or Pretzel syndrome, is a rare brain disorder that affects children from birth. The name describes three of its main features: polyhydramnios (too much fluid around the baby during pregnancy), megalencephaly (an unusually large brain), and epilepsy (recurring seizures that are hard to control). The condition is caused by changes in a gene called STE20-related kinase adaptor alpha (STRADA), which plays an important role in how brain cells grow and develop. When this gene does not work properly, brain cel
How is Polyhydramnios-megalencephaly-symptomatic epilepsy syndrome inherited?
Polyhydramnios-megalencephaly-symptomatic epilepsy syndrome follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Polyhydramnios-megalencephaly-symptomatic epilepsy syndrome typically begin?
Typical onset of Polyhydramnios-megalencephaly-symptomatic epilepsy syndrome is neonatal. Age of onset can vary across affected individuals.